Citations

Mayo Clinic

Showing 10 of 108602 citations.

Telomerase Expression Related with Poor Immune Response to HCV Core Antigen in Egyptian HCV Patients’ PBMCs
Ibrahim, Iman , El-Sahar, Adel Ahmed, Elrefaei, Mohamed , El-Sheikh, Nabila, Ali, Ola Sayed M. , EL-Sahar, Adel Ahmed

No container title available | February 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2617198/v1 Get It

Abstract Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. This study aimed to assess serum hTERT level and its relation to the progression of liver disease. Also, it aimed to assess the effect of HCV core protein on memory T-cells in HCV patients with or without HCC, and the correlation between memory cells phenotype and the progression of the disease in the same patients. hTERT level in serum was assessed through relative quantitative RT-PCR. Flow cytometric analysis was used to assess T-cells responsiveness (as IFN-γ secretion) before and after stimulation with HCV core protein, and memory CD8+ cells phenotype using several differentiation markers. hTERT was found to be increased in a stepwise manner upon comparing its level in controls, chronic hepatitis patients, cirrhotic patients, and HCC patients. T-cells showed a similar manner of stepwise decrease in response (decreased IFN-γ secretion) in HCC patients compared to HCV patients without HCC and controls. Also, late differentiated memory cells (CD8+ CD27- CD28- CD45RA+CCR7-) were depleted in HCC patients compared to HCV patients without HCC. In conclusion, these results suggest a negative correlation between hTERT and IFN-γ secretion by T- cells in HCV patients and that this relationship along with the depletion of late differentiated memory cells could help the progression of liver disease to HCC.
5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
Neelapu, Sattva S. , Jacobson, Caron A. , Ghobadi, Armin , Miklos, David B. , Lekakis, Lazaros J. , Oluwole, Olalekan O. , Lin, Yi , Braunschweig, Ira , Hill, Brian T. , Timmerman, John M. , Deol, Abhinav , Stiff, Patrick J. , McSweeney, Peter A., Herrera, Alex F. , Bartlett, Nancy L. , Bot, Adrian A., Shen, Rhine R. , Dong, Jinghui , Singh, Kanwarjit, Miao, Harry , Zheng, Yan , Stiff, Patrick J , Flinn, Ian W , Farooq, Umar , Goy, Andre Henri , Munoz, Javier L , Herrera, Alex F , Bartlett, Nancy L , Oluwole, Olalekan O , Miklos, David B , Ghobadi, Armin , Reagan, Patrick Michael , Flinn, Ian W. , Muñoz, Javier , Siddiqi, Tanya , Chavez, Julio C , Bot, Adrian , Kim, Jaeyeon , Locke, Frederick L.

Blood | February 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2022018893 | PMID 36821768 Get It

In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we aimed to assess survival and safety in ZUMA-1 after 5 years of follow-up. Eligible adults with refractory LBCL (diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma) received lymphodepleting chemotherapy followed by axi-cel infusion targeted at 2×106 cells/kg. Investigator-assessed response, updated survival, safety, and pharmacokinetic outcomes were assessed in treated patients. The objective response rate in the 101 treated patients was 83% (58% complete response rate), and with a median follow-up of 63.1 months, responses were ongoing at data cutoff in 31%. Median overall survival (OS) was 25.8 months and the estimated 5-year OS rate was 42.6%. Disease-specific survival (excluding deaths unrelated to disease progression) estimated at 5 years was 51.0%. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up. Peripheral blood B cells were detectable in all evaluable patients at 3 years with polyclonal B-cell recovery in 91%. Ongoing responses at 60 months were associated with early CAR T-cell expansion. In conclusion, this 5-year follow-up analysis of ZUMA-1 demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL. Protracted B-cell aplasia was not required for durable responses. These findings support the curative potential of axi-cel in a subset of patients with aggressive B-cell lymphomas. ClinicalTrials.gov, number NCT02348216
Anatomic and Functional Imaging of Immunoglobulin G4–related Disease and Its Mimics
Huynh, Kenneth N. , Kong, Min J., Nguyen, Ba D. , Nguyen, B D , Kong, Min J.

RadioGraphics | February 23, 2023 | Volume: 43 | Issue: 3 | Pages: No page available

10.1148/rg.220097 | PMID 36821510 Get It

The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors
Charbonneau, Martine , Harper, Kelly , Brochu‐Gaudreau, Karine , Perreault, Alexis, Roy, Laurent-Olivier , Tian, Shulan , Fortin, David , Dubois, Claire M. , Lucien, Fabrice , Dubois, Claire M , Lucien, Fabrice

Neuro-Oncology | February 23, 2023 | Volume: 25 | Issue: 9 | Pages: 1605-1616

10.1093/neuonc/noad047 | PMID 36821432 Get It

Abstract Background High-grade gliomas (HGG) are aggressive brain tumors associated with short median patient survival and limited response to therapies, driving the need to develop tools to improve patient outcomes. Patient-derived xenograft (PDX) models, such as mouse PDX, have emerged as potential Avatar platforms for personalized oncology approaches, but the difficulty for some human grafts to grow successfully and the long time required for mice to develop tumors preclude their use for HGG. Methods We used a rapid and efficient ex-ovo chicken embryo chorioallantoic membrane (CAM) culture system to evaluate the efficacy of oncologic drug options for HGG patients. Results Implantation of fresh glioma tissue fragments from 59 of 60 patients, that include difficult-to-grow IDH-mutated samples, successfully established CAM tumor xenografts within 7 days, with a tumor take rate of 98.3%. These xenografts faithfully recapitulate the histological and molecular characteristics of the primary tumor, and the ability of individual fragments to form tumors was predictive of poor patient prognosis. Treatment of drug-sensitive or drug-resistant xenografts indicates that the CAM-glioma assay enables testing tumor sensitivity to temozolomide and carboplatin at doses consistent with those administered to patients. In a proof-of-concept study involving 14 HGG patients, we observed a correlation of 100% between the CAM xenograft response to temozolomide or carboplatin and the clinical response of patients. Conclusion The CAM-glioma model is a fast and reliable assay that has the potential to serve as a complementary model to drug discovery and a real-time Avatar platform to predict the best treatment for HGG patients.
The ROWAN study: Safety and efficacy of transarterial radioembolization with Y-90 glass microspheres and the STRIDE regimen in hepatocellular carcinoma.
Toskich, Beau , He, Aiwu Ruth

Journal of Clinical Oncology | February 23, 2023 | Volume: 41 | Issue: 4_suppl | Pages: TPS622-TPS622

10.1200/jco.2023.41.4_suppl.tps622 Get It

TPS622 Background: In patients with early and intermediate hepatocellular carcinoma (HCC) who are ineligible for resection, thermal ablation, or liver transplant, transarterial radioembolization (TARE) with yttrium-90 glass microspheres has shown superior efficacy compared to transarterial chemoembolization; a subset of patients progress despite effective local therapy. Immunotherapy using the single tremelimumab regular interval durvalumab (STRIDE) regimen has demonstrated superior overall survival to sorafenib in advanced HCC. Recent work showed that TARE upregulates both the innate and adaptive immune systems. The possibility for TARE and STRIDE to have additive or synergistic effects when combined is of current scientific and clinical interest. The primary objective of the Phase II ROWAN Study is to assess the objective response rate and durability of local tumor control with TARE followed by STRIDE vs. TARE alone. Methods: ROWAN is a global, open-label, prospective, multicenter randomized controlled trial comparing treatment with TARE using glass microspheres followed by the STRIDE regimen (a single dose of 300 mg tremelimumab combined with 1500 mg monthly dose of durvalumab for 18 months) to TARE alone in HCC. ROWAN will include 150 patients across approximately 20 study sites in North America and Europe. Key inclusion criteria: HCC, diagnosed by radiographic imaging or histology; ineligible for or declined liver resection, thermal ablation, or transplantation; Child-Pugh A; ECOG 0; life expectancy ≥6 months; treatment naïve; unilobar tumor; measurable by mRECIST; tumor volume ≤25% of whole liver volume; and untreated future liver remnant volume ≥30% of whole liver volume. Key exclusion criteria: extrahepatic metastases; shunt fraction with a lung dose of >30 Gy; macrovascular invasion; infiltrative disease not evaluable by mRECIST; history of any organ allograph; autoimmune or inflammatory disorder; current use of immunosuppressive medication; history of malignancy other than HCC within past 3 years; and active infection. Patients will be randomized in a 1:1 ratio to two study arms (TARE followed by STRIDE or TARE alone) using two stratification factors (TARE treatment goal [ablative vs. non-ablative] and alpha fetoprotein level [>400 vs. ≤400 ng/mL]). Tumor and blood samples will be collected for correlative studies. Co-primary efficacy endpoints are objective response rate and duration of response (localized mRECIST). The primary safety endpoint is the number of adverse events (AEs) and serious AEs. Interim statistical analyses will be conducted after 25 patients have been randomized to each arm and completed the second imaging assessment 6 months post-randomization; final analysis will be after the last evaluable patient has completed the 18 months follow-up visit post-randomization or discontinued treatment. Clinical trial information: 05063565 .
Pharmacokinetics and RP2D analysis from ETCTN 10388: A phase I trial of triapine and lutetium Lu-177 dotatate in well-differentiated somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Chauhan, Aman, Christner, Susan M., Kunos, Charles A., Khurana, Aman , Khouli, Riham El , Weiss, Heidi, Evers, Mark B., Kohn, Elise C. , Kolesar, Jill , Anthony, Lowell , Beumer, Jan Hendrik , Weiss, Heidi, Yan, Donglin , Soares, Heloisa P. , Hálfdánarson, Þorvarður R. , Li, Daneng , Carson, William E. , Ivy, S. Percy , Rubinstein, Larry , Arnold, Susanne M. , Konda, Bhavana

Journal of Clinical Oncology | February 23, 2023 | Volume: 41 | Issue: 4_suppl | Pages: 648-648

10.1200/jco.2023.41.4_suppl.648 Get It

648 Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme for conversion of ribonucleoside diphosphate to deoxyribonucleotide diphosphate, and thus repair of DNA in this setting. ETCTN 10388 evaluated safety of combination Lu-177 DOTATATE, a beta-emitting radionuclide in combination with triapine, a ribonucleotide reductase (RNR) inhibitor. Methods: This investigator initiated, NCI sponsored, multicenter phase 1 trial, enrolled a total of 31 patients in the dose escalation [using the Bayesian optimal interval design (BOIN)] and dose expansion cohorts. Oral triapine was administered on days 1-14 and Lu-177 DOTATATE [200 mCi] intravenously on day 1 of every 56-day cycle. A total of 4 cycles were administered. All enrolled patients had blood samples collected for triapine pharmacokinetic (PK) analysis in EDTA tubes prior to and at 0.5, 1, 1.5, 2, 3, 4, 6, and 8 h after oral administration during cycle 1. Results: Five patients were enrolled in triapine Dose Level 1 (100 mg/day), twenty-five to dose level two (150 mg/day), and one patient to dose level three (200 mg/day). PK data were available for 12 patients enrolled in the dose escalation cohort. The geometric mean (SD) AUC0-inf was 1159 (1.22) µg/L•h for the 100mg dose level and 1862 (1.76) µg/L•h for the 150 mg dose level, suggesting that exposure increased with dose, and inter-patient variability was as expected for an oral agent. Triapine PK parameter values observed in this trial, were comparable to previous reports that used a previous formulation [ 1 ]. While exposure was similar, variability appeared smaller with the current oral formulation. Adverse events (AE) were assessed in all 31 patients per CTCAE 5.0. A total of one DLT in dose level 1, seven DLTs (Transient cytopenia; primarily neutropenia and rarely thrombocytopenia) in dose level 2, and one grade 5 DLT (Death probably from progressive cancer and carcinoid heart disease but possibly from trial drugs) in dose level 3 were observed. Detailed AE profile will be presented at the meeting. Conclusions: The RP2D of triapine is 150 mg QD on days 1-14 in combination with Lu-177 DOTATATE on day 1 of every 56-day cycle. Clinical trial information: 04234568 .
Nasal Swell Body Characteristics in Patients With Septal Perforation
Brake, Daniela A. , Snider, Sam, Miglani, Amar , Bansberg, Stephen F. , Bansberg, Stephen F , Hamilton, Grant

OTO Open | February 23, 2023 | Volume: 7 | Issue: 1 | Pages: No page available

10.1002/oto2.43 | PMID 36998544 Get It

AbstractObjectiveTo determine whether septal perforations have an effect on nasal swell body (NSB) size.Study DesignRetrospective cohort study.SettingTwo tertiary academic medical centers.MethodsComputed tomography maxillofacial scans of 126 patients with septal perforation and 140 control patients from November 2010 to December 2020 were evaluated. Perforation etiology was determined. Measurements included perforation length and height and swell body width, height, and length. Swell body volume was calculated.ResultsThe width and volume of the NSB are significantly smaller in perforation patients when compared to controls. The swell body is significantly smaller and thinner in perforations exceeding 14 mm in height compared to small perforations. Perforation etiology groupings into prior septal surgery, septal trauma, septal inflammatory, and mucosal vasoconstriction categories all demonstrated decreased swell body volume and width compared to controls. Inflammatory etiology had the greatest decrease in swell body size. The hemi‐swell body on the contralateral side of a septal deviation is significantly thicker than the ipsilateral side.ConclusionThe NSB is smaller in patients with septal perforation regardless of perforation size or etiology.
Research Priorities of Individuals and Caregivers With Lewy Body Dementia
Holden, Samantha K. , Bedenfield, Noheli , Taylor, Angela , Schwilk, Chris, Duda, John E., Shill, Holly A. , Paulson, Henry L. , Stacy, Kelly E. , Wood, Julia T., Corsentino, Pamela, Sha, Sharon J. , Goldman, Jennifer G. , Amodeo, Katherine , Taylor, John‐Paul , Armstrong, Melissa J. , Goldman, Jennifer G , Taylor, John Paul , Paulson, Henry L , Armstrong, Melissa J , Bayram, Ece , Fleisher, Jori , Wood, Julia, Litvan, Irene , Irwin, David J. , Quinn, Joseph F. , Boeve, Bradley F.

Alzheimer Disease & Associated Disorders | February 23, 2023 | Volume: 37 | Issue: 1 | Pages: 50-58

10.1097/wad.0000000000000545 | PMID 36821177 Get It

Introduction: Lewy body dementia (LBD) is common, yet under-recognized and under-researched. To plan studies with the highest impact, engagement of the community personally affected by these conditions is essential. Methods: A web-based survey of people living with LBD and current and former caregivers of people with LBD queried research priorities through forced ranking and exploration of burden of LBD symptoms. Specific caregiving needs in LBD and perceptions of research participation were also investigated. Results: Between April 7, 2021 and July 1, 2021, 984 responses were recorded. Top research priorities included disease-modifying therapies and improved disease detection and staging. People with LBD were interested in pathophysiology and more bothered by motor symptoms; caregivers were interested in risk factors and symptomatic therapies and more bothered by neuropsychiatric symptoms. Few available LBD treatments and resources were rated as helpful, and many valuable services were never received. Previous participation in LBD research was infrequent, but interest was high. Discussion: People with LBD and caregivers highlighted the need for research across all aspects of LBD, from pathophysiology and disease modification to prognosis, education, symptomatic treatments, and caregiver support. Funders should increase support for all aspects of LBD research to target the many needs identified by individuals and families living with LBD.
Development and Performance Of a Multiplex PCR Assay For the Detection of Bacteria in Sterile Body Fluids
Johnson, Coreen , Marquez, Christopher P. , Olson, Damon R. , Ward, Tabitha, Cheney, Stephen, Hulten, Tina, Ton, Trang T., Webb, CR, Dunn, James J. , Marquez, Christopher, Dunn, James , Olson, Damon R , Cheney, Stephen

Future Microbiology | February 23, 2023 | Volume: 18 | Issue: 3 | Pages: 187-195

10.2217/fmb-2022-0226 | PMID 36820638 Get It